Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, placebo controlled, multi-center, multi-nation, clinical trial of JadiCell™ Universal Donor Stem Cell Drug in the patients with COVID-19 associated lung failure

X
Trial Profile

A double-blind, randomized, placebo controlled, multi-center, multi-nation, clinical trial of JadiCell™ Universal Donor Stem Cell Drug in the patients with COVID-19 associated lung failure

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allogeneic umbilical cord mesenchymal stem cells-Therapeutic Solutions International (Primary)
  • Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Therapeutic Solutions International
  • Most Recent Events

    • 20 Sep 2022 According to a Therapeutic Solutions International media release, the company entered into an agreement with GHS Investments, LLC to purchase up to $10,000,000 of Registered Common Stock to secure financing to complete this study.
    • 25 Aug 2022 According to a Therapeutic Solutions International media release, the company has announced filing with the Food and Drug Administration (FDA) an amendment to the trial requesting expansion of eligible patients with all patients suffering from Acute Respiratory Distress Syndrome (ARDS) regardless of cause.
    • 18 Jul 2022 According to a Therapeutic Solutions International media release, company announced granting of Emergency IND # 28685 and a May Proceed Notification from the Food and Drug Administration (FDA) for the treatment of advanced COVID-19 ARDS outside
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top